Influenza [strain A/H5N1] (quadrivalent) vaccine is under clinical development by Seqirus and currently in Phase III for Influenzavirus B Infections. According to GlobalData, Phase III drugs for Influenzavirus B Infections have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Influenza [strain A/H5N1] (quadrivalent) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Influenza [strain A/H5N1] (quadrivalent) vaccine overview
MF59-eTIV-H5N1 (tetravalent influenza vaccine) is under development for influenza A and B infection. The therapeutic candidate is administered as intramuscular injection. The therapeutic candidate contains both interpandemic strains and H5N1 strain. MF59 is an adjuvant. It is the first oil-in-water adjuvant. MF59 helps elicit broad, cross-reactive immune responses against a wide range of influenza strains. The therapeutic candidate consist of a highly purified surface antigen of influenza virus strains, types A and B, H5N1 strain and MF59.
It was under development for the prevention of H5N1 infections.
Seqirus overview
Seqirus, a subsidiary of CSL Ltd, is a pharmaceutical company that manufactures and markets influenza, antivenoms, and pharmaceutical products. The company is headquartered in Maidenhead, Berkshire, the UK.
For a complete picture of Influenza [strain A/H5N1] (quadrivalent) vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
